Figure 4.

Cumulative mortality from all causes in the trandolapril group compared with the placebo group over 10 years of follow-up. Reprinted with permission from Buch P, Rasmussen S, Abildstrom SZ, et al 2005. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur Heart J, 26:145–52. Copyright © 2005 European Society of Cardiology.